@alliance-org.bsky.socialFDA approves new treatment option, atezolizumab in combination with chemotherapy, for patients with stage III dMMR colon cancer based on results from the phase III ATOMIC trial led by Alliance. Learn more at https://bit.ly/FDA-ATOMIC #NCI #NCTN #CancerResearch #CRCsm
@johnprensner.bsky.social
@penningtonbiomed.bsky.socialWe were pleased to welcome Dr. Lucio Miele to Pennington Biomedical to share an update on the pursuit of National Cancer Institute (NCI) designation for Louisiana and the Gulf South. #PenningtonBiomedical #LSU #CancerResearch #NCI #Louisiana
@stocktitan.net#NCI Neo-Concept International Group Holdings Ltd Announces Pricing of $2.0 Million Registered Direct Offering
@petersuber.fediscience.org.ap.brid.gy"NIH Employees Lived in A Culture of Fear, So They Started Keeping Receipts."
https://www.psychologicalscience.org/publications/observer/nih-culture-fear.html
An interview with Sylvia Chou, an 18 year vet of the #NIH, and former program director at the National Cancer Institute (#NCI).
h/t […]
@alliance-org.bsky.socialTrial Tuesday! Jennifer Ligibel MD of the Dana-Farber and Kathryn Schmitz PhD of @upmchillmancc.bsky.social lead Alliance A222302 studying the feasibility of a telehealth exercise program for cancer patients with the goal of reducing fatigue and disability. https://bit.ly/DEFEND-trial #oncsky #nci
@nci-cipnet.org📢 Registration is open for the 4th Biennial Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Meeting!
📅 September 28–30, 2026
💻 Virtual & free to attend
Register: events.cancer.gov/cadrg/tacpad...
#CancerPrevention #CancerResearch #TACPAD #CancerInterception #NCI
@alliance-org.bsky.socialDr. Brad McGregor of Dana-Farber leads Alliance A032201 (STRIKE) to see if adding the anti-cancer drug tivozanib to the standard treatment of immunotherapy after surgery helps patients with high-risk renal cell cancer. Learn more: https://bit.ly/Alliance-A032201 #NCI #NCTN #PCSM
